

- Hematopoiesis, 510f  
 embryonic, 216  
 extramedullary, 506
- Hematopoietic stem cell(s), sources of, 269
- Hematopoietic stem cell transplantation (HSCT), 269–270  
 for aplastic anemia, 517  
 complications of, 270  
 for Fanconi anemia, 517  
 immunodeficiency diseases curable by, 269, 269t  
 major histocompatibility complex compatibility in, 269  
 for sickle cell anemia, 520
- Hematuria, 558–560  
 benign familial, 558–559  
 clinical manifestations of, 558–559  
 diagnostic studies of, 558t, 559, 559f  
 due to renal disease, 554t  
 etiology and epidemiology of, 558  
 gross, 558  
 microscopic, 558  
 prognosis and prevention of, 560  
 therapy for, 559
- Heme, in erythropoiesis, 506–509
- Heme iron, 104
- Hemiparesis, due to cerebral palsy, 35t
- Hemiplegia  
 of childhood, congenital, 631  
 due to cerebral palsy, 35t
- Hemochromatosis, with  $\beta$ -thalassemia major, 518
- Hemodialysis, for chronic kidney disease, 563
- Hemodynamics, for cardiomyopathy(ies), 503t
- Hemoglobin  
 Bart, 518  
 fetal, 190, 191f, 216, 509  
 normal values for, 508t  
 production of, 509
- Hemoglobin A, 509
- Hemoglobin C, 518
- Hemoglobin D, 518
- Hemoglobin E, 518
- Hemoglobin electrophoresis  
 for hemoglobinopathies, 520  
 in newborn screening, 21
- Hemoglobin F, 190, 191f, 216, 509
- Hemoglobin H, 515t
- Hemoglobin level(s)  
 after birth, 216  
 in anemia, 509
- Hemoglobin-oxygen dissociation curve, fetal, 190, 191f
- Hemoglobin S, 518
- Hemoglobin S- $\beta$ -thalassemia, 518–519, 519t
- Hemoglobin SC disease, 518–519, 519t
- Hemoglobin SS disease, 518–519, 519t. *see also* Sickle cell disease
- Hemoglobinopathy(ies)  
 alpha chain, 518  
 beta chain, 518  
 hemolytic anemia due to, 510f, 518  
 laboratory diagnosis of, 520
- Hemoglobinuria, paroxysmal nocturnal, 516t
- Hemolysis  
 isoimmune, 522, 522f  
 in newborn  
 diagnosis and management of, 218–219  
 etiology of, 216  
 nonimmune causes of, 218
- Hemolytic anemia. *see* Anemia; hemolytic
- Hemolytic crisis, in sickle cell anemia, 520t
- Hemolytic disease, of the newborn, 217
- Hemolytic uremic syndrome (HUS), 366t, 367, 560  
 clinical manifestations of, 560  
 diagnostic studies of, 560, 560t  
 due to thrombotic microangiopathy, 528  
 etiology and epidemiology of, 560  
 GI bleeding due to, 427t  
 glomerular injury due to, 558  
 schistocytes in, 513f  
 treatment and prognosis for, 560  
 due to roseola infantum, 333
- Hemophagocytic syndrome  
 due to roseola infantum, 333  
 virus-associated, 516t
- Hemophilia, 528–530  
 clinical manifestations of, 529  
 etiology and epidemiology of, 523  
 etiology of, 528  
 laboratory studies of, 529  
 treatment of, 529
- Hemophilia A, 528, 529t  
 genetic basis for, 151t
- Hemophilia B, 528, 529t
- Hemoptysis, due to pulmonary hemorrhage, 474
- Hemorrhage  
 airway, 474  
 alveolar, 474  
 brain, due to hypernatremia, 115  
 contusion, 638t  
 epidural, 638t  
 fetal-maternal, 218  
 intracranial  
 in neonatal alloimmune thrombocytopenic purpura (NATP), 527  
 in newborn, 226  
 post-traumatic, 638t  
 intraparenchymal, 638t  
 in newborn  
 intracranial, 226  
 intraventricular. *see* Intraventricular hemorrhage (IVH); in newborn  
 periventricular, 226  
 retinal, 202  
 subarachnoid, 226  
 subconjunctival, 202  
 subdural, 226  
 pulmonary, 473–474  
 clinical manifestations of, 473–474  
 diagnostic studies for, 474  
 differential diagnosis of, 474, 474t  
 etiology of, 473  
 hemoptysis due to, 474  
 treatment of, 474  
 subarachnoid  
 due to trauma, 638t  
 in newborn, 226  
 subdural, 638t  
 due to child abuse, 72, 72f  
 in newborn, 226
- Hemorrhagic disease of the newborn, 102–103  
 due to vitamin K deficiency, 222
- Hemorrhagic disorders. *see* Hemostatic disorder(s)
- Hemorrhagic strokes, 630–631
- Hemosiderosis, idiopathic pulmonary, 473
- Hemostasis  
 developmental, 523  
 normal, 523, 524f
- Hemostatic disorder(s), 523–531  
 clinical manifestations of, 524  
 clotting factors disorders, 528  
 disseminated intravascular coagulation (DIC) as, 530–531  
 etiology of, 528  
 hemophilia as, 528–530
- Hemostatic disorder(s) (*Continued*)  
 thrombosis as, 531, 531f  
 von Willebrand disease as, 529t, 530  
 differential diagnosis of, 526–531  
 etiology and epidemiology of, 523, 525f, 526t  
 laboratory testing for, 524–526, 526t  
 in newborn  
 clinical manifestations and differential diagnoses of, 222–223  
 etiology and pathogenesis of, 223  
 of platelet function, 528  
 of platelet number, 526, 527f  
 idiopathic thrombocytopenic purpura (ITP) as, 527–528  
 sequestration thrombocytopenia due to decreased platelet production as, 526–527  
 thrombocytopenia due to peripheral destruction as, 527  
 Wiskott-Aldrich syndrome as, 528
- Hemostatic plug, 524f, 531f
- Hemotympanum, 638
- Henoch-Schönlein purpura (HSP), 301–303  
 clinical manifestations of, 302, 302f  
 complications of, 302–303  
 diagnostic criteria for, 302t  
 differential diagnosis of, 302, 304t  
 epidemiology of, 301  
 etiology of, 301  
 laboratory and imaging studies of, 302  
 prognosis for, 304  
 treatment of, 302
- Heparin  
 for disseminated intravascular coagulation, 531  
 for thrombosis, 531
- Hepatic encephalopathy, 447–449  
 stages of, 448t  
 treatment of, 448t
- Hepatic failure, due to inborn errors of metabolism, 168t
- Hepatic fibrosis, in autosomal recessive polycystic kidney disease, 566
- Hepatic synthetic function, for gastrointestinal symptoms, 417
- Hepatitis  
 autoimmune, 450, 449t  
 fulminant, 373–374  
 neonatal, 444  
 nonalcoholic fatty, 450  
 viral, 369–372  
 clinical manifestations of, 370, 371f  
 complications and prognosis of, 373–374  
 differential diagnosis of, 371  
 epidemiology of, 369–370  
 etiology of, 369  
 laboratory and imaging studies for, 370–371  
 prevention of, 374  
 treatment of, 371–372  
 viral, laboratory and imaging studies for, 449t  
 vomiting due to, 423t
- Hepatitis A (HepA) vaccine, 372, 317–318, 319f–322f
- Hepatitis A virus (HAV), 370t  
 clinical manifestations of, 370, 371f  
 complications and prognosis of, 373–374  
 epidemiology of, 369–370  
 laboratory studies for, 370–371  
 prevention of, 374  
 treatment of, 371–372
- Hepatitis B (HepB) vaccine, 317–318, 319f–322f
- Hepatitis B surface antigen (HbsAg), 369, 371
- Hepatitis B virus (HBV), 369, 370t  
 clinical manifestations of, 370, 371f  
 complications and prognosis of, 373–374